Sorry, you need to enable JavaScript to visit this website.
Skip to main content

This site is intended for US healthcare professionals only.

This site is intended for US healthcare professionals only.

Kill it for your patients

These BREXAFEMME resources can help

From requesting virtual or in-person visits with representatives to sharing product and savings information with your colleagues and patients, we’re here to support you. Explore the resources below to learn more.

For you

Icon of a brochure

Need a quick refresher on BREXAFEMME?

 

 

Icon of prescribing information

Ready to prescribe BREXAFEMME?

For your patients

Icon of a pamphlet

Download your patients on all things BREXAFEMME.

Icon of a hand holding a savings card

Cure the yeast infection for less.1,2

Icon representing the broad-spectrum, fungicidal activity of BREXAFEMME® (ibrexafungerp tablets)

Don’t just inhibit yeast growth. Kill it with BREXAFEMME.1

Icon of a box labeled Rx

You’ve prescribed the cure.1,2 Now it’s easy for your patients to find it.

MoA=mechanism of action.

SAY NO MORE to vaginal yeast infections.
Prescribe BREXAFEMME today.

SAY NO MORE to vaginal yeast infections. Prescribe BREXAFEMME today.

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References

1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Data on file. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

/ / / /
  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

Read full Important Safety Information